Bio-Path Holdings (NASDAQ:BPTH) has seen a rise of 39,489 shares or 3.1% in the short interest. The remaining shorts are 1.6% of the total floated shares. The net short interest, as on June 15,2016, stood at 1,301,428 shares and the stocks days to cover will be 7 by factoring in the average per day volume of 197,393 shares. On May 31,2016, 1,261,939 shares were shorted. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Bio-Path Holdings (NASDAQ:BPTH): The stock opened at $2.10 on Friday but the bulls could not build on the opening and the stock topped out at $2.23 for the day. The stock traded down to $2.02 during the day, due to lack of any buying support eventually closed down at $2.14 with a loss of -1.83% for the day. The stock had closed at $2.18 on the previous day. The total traded volume was 8,135,729 shares.
The company shares have rallied 96.33% from its 1 Year high price. On Apr 5, 2016, the shares registered one year high at $3.19 and the one year low was seen on Sep 24, 2015. The 50-Day Moving Average price is $2.48 and the 200 Day Moving Average price is recorded at $2.01.
Stocks of Bio-Path Holdings (NASDAQ:BPTH) rallied by 9.18% during the past week but lost 22.18% on a 4-week basis. The company has outperformed the S&P 500 by 11% in the past week but underperformed the index by 19.83% in the last 4 weeks.
Bio-Path Holdings, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer drugs under a license arrangement. The Companys lead cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP1001) is undergoing clinical trials. The Companys two liposomal antisense drug candidates are focused to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and follicular lymphoma. BP1001 is its lead liposome delivered antisense drug candidate, which has been clinically tested in patients having AML, CML, MDS and ALL. BP-100-1.02 (Bcl-2 or BP1002) is its second liposome delivered antisense drug candidate. Clinical targets for BP1002 include lymphoma, breast cancer, colon cancer, prostate cancer and leukemia. The Company has a drug delivery platform technology with composition of matter intellectual property for systemic delivery of antisense.